Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3L0F8)

• Drug Name: 3-iodothyronamine Drug Info
• Synonyms: CHEMBL201002; 3'-iodothyronamine; 3''-iodothyronamine; GTPL2145; SCHEMBL13886595; BDBM50181801; 4-[4-(2-aminoethyl)phenoxy]-2-iodophenol

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9950514
  ChEBI ID: CHEBI:89700
  CAS Number: CAS 712349-95-6
  TTD Drug ID: DM3L0F8

Molecule-Related Drug Atlas

Drug(s) Targeting Trace amine-associated receptor-1 (TAAR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[4]
Lisdexamfetamine	DM6W8V5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[5]
Dextroamphetamine	DMMIHVP	Attention deficit hyperactivity disorder	6A05.Z	Approved	[4]
Hydroxyamphetamine Hydrobromide	DMQSGM0	Horner syndrome	8D8A.1	Approved	[6]
SEP-363856	DMG2QP4	Schizophrenia	6A20	Phase 3	[7]
NT0202	DMCMIJ1	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[4]
SPD-465	DM7NV1I	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[4]
RG-7351	DMFGR98	Major depressive disorder	6A70.3	Phase 1	[8]
tyramine	DM4UXT1	Discovery agent	N.A.	Investigative	[9]
EPPTB	DMK3VID	Discovery agent	N.A.	Investigative	[10]

Drug(s) Affected By Sodium/hydrogen exchanger 9 (SLC9A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[14]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[15]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[16]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[17]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[19]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[11]

Drug(s) Affected By Proton-coupled folate transporter (SLC46A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pemetrexed	DMMX2E6	Central nervous system lymphoma	2B33.5	Approved	[20]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[21]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[22]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[23]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[24]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[25]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[27]

Drug(s) Affected By Solute carrier family 7 member 14 (SLC7A14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[28]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[30]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[33]

Drug(s) Affected By Ammonium transporter Rh type C (RHCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ammonia	DMOEVK6	Coronary artery disease	BA80	Approved	[34]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[35]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[36]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[37]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[38]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[39]

Drug(s) Affected By Solute carrier organic anion transporter family member 4A1 (SLCO4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[28]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[43]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[46]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[47]

Drug(s) Affected By Sodium/hydrogen exchanger 6 (SLC9A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[43]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[52]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[19]

Drug(s) Affected By Solute carrier family 28 member 3 (SLC28A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[41]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[53]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[54]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[55]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[55]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[56]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[57]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[58]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[37]

Drug(s) Affected By Solute carrier family 45 member 4 (SLC45A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[59]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[60]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[61]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[62]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[63]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[64]
paraquat	DMR8O3X	Discovery agent	N.A.	Investigative	[65]

Drug(s) Affected By Monocarboxylate transporter 2 (SLC16A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[66]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[67]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[69]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[70]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]

Drug(s) Affected By Solute carrier family 35 member C2 (SLC35C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[71]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[72]
[3H]methyltrienolone	DMTSGOW	Discovery agent	N.A.	Investigative	[73]

Drug(s) Affected By Cationic amino acid transporter 2 (SLC7A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[41]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[75]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[75]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[76]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]

Drug(s) Affected By Solute carrier organic anion transporter family member 6A1 (SLCO6A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[77]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[78]

Drug(s) Affected By Proton-coupled zinc antiporter SLC30A8 (SLC30A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[63]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[54]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[79]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[80]

Drug(s) Affected By Long-chain fatty acid transport protein 1 (SLC27A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[81]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[75]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[75]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[43]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[82]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[71]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[14]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[15]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[83]

Drug(s) Affected By Sialin (SLC17A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[84]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[75]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[75]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[16]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[85]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[19]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[79]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[86]

Drug(s) Affected By Sodium/hydrogen exchanger 5 (SLC9A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[63]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[14]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[79]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[72]

Drug(s) Affected By Solute carrier organic anion transporter family member 3A1 (SLCO3A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[71]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[17]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Simvastatin acid	DM18QHT	N. A.	N. A.	Phase 3	[88]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[58]

Drug(s) Affected By Solute carrier organic anion transporter family member 5A1 (SLCO5A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[89]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[14]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[90]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[17]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[91]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[92]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[72]

Drug(s) Affected By Membrane-associated transporter protein (SLC45A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[75]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[75]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[36]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[93]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[72]
Forskolin	DM6ITNG	Solid tumour/cancer	2A00-2F9Z	Investigative	[93]

Drug(s) Affected By Solute carrier organic anion transporter family member 1A2 (SLCO1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trospium chloride	DM32XZT	Discovery agent	N.A.	Approved	[95]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[96]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[97]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[98]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[26]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[78]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[27]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[99]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[79]

Drug(s) Affected By High affinity cationic amino acid transporter 1 (SLC7A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[102]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[103]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[26]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[49]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[103]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]

Drug(s) Affected By Sodium/hydrogen exchanger 8 (SLC9A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[105]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[84]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[59]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[14]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[106]

Drug(s) Affected By Equilibrative nucleobase transporter 1 (SLC43A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[107]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[108]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[36]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[59]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[14]
Bortezomib	DMNO38U	Leukemia		Approved	[71]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[108]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[109]

Drug(s) Affected By Inactive sodium-dependent neutral amino acid transporter B(0)AT3 (SLC6A18)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[63]

Drug(s) Affected By Glucose-6-phosphate exchanger SLC37A1 (SLC37A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[41]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[50]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[110]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
Nitrobenzanthrone	DMN6L70	N. A.	N. A.	Investigative	[111]

Drug(s) Affected By Equilibrative nucleoside transporter 2 (SLC29A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[109]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[76]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[109]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[17]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[54]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[112]
Uridine	DMQTREB	Depression	6A70-6A7Z	Approved	[113]

Drug(s) Affected By Sodium/hydrogen exchanger 7 (SLC9A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[114]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[114]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[116]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[37]
benzamil	DM57SVW	Discovery agent	N.A.	Investigative	[114]

Drug(s) Affected By Solute carrier organic anion transporter family member 4C1 (SLCO4C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[117]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[66]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[105]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[59]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[44]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[118]

Drug(s) Affected By Sodium-independent sulfate anion transporter (SLC26A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[41]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[59]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[119]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[120]
Bortezomib	DMNO38U	Leukemia		Approved	[71]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[31]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[85]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]

Drug(s) Affected By Nucleotide sugar transporter SLC35D2 (SLC35D2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[121]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[18]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[79]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[19]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[110]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[94]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[72]

Drug(s) Affected By High affinity copper uptake protein 1 (SLC31A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[122]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[122]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[28]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[66]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[12]
TRIENTINE	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[122]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[43]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[124]

Drug(s) Affected By Calcium/manganese antiporter SLC30A10 (SLC30A10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[28]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[66]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[105]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[125]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[11]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[118]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[45]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[17]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[11]

Drug(s) Affected By Sodium/hydrogen exchanger 4 (SLC9A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[91]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[116]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Trace amine-associated receptor-1 (TAAR1)	TTIU98M	TAAR1_HUMAN	Agonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Ammonium transporter Rh type C (RHCG)	OT1MTYUH	RHCG_HUMAN	Regulation of Drug Effects	[3]
Calcium/manganese antiporter SLC30A10 (SLC30A10)	OTXM5JW4	ZNT10_HUMAN	Regulation of Drug Effects	[3]
Cationic amino acid transporter 2 (SLC7A2)	OTAMWBVM	CTR2_HUMAN	Regulation of Drug Effects	[3]
Equilibrative nucleobase transporter 1 (SLC43A3)	OTR60ZLA	S43A3_HUMAN	Regulation of Drug Effects	[3]
Equilibrative nucleoside transporter 2 (SLC29A2)	OTUAOB8T	S29A2_HUMAN	Regulation of Drug Effects	[3]
Glucose-6-phosphate exchanger SLC37A1 (SLC37A1)	OTSYK97W	G6PT2_HUMAN	Regulation of Drug Effects	[3]
High affinity cationic amino acid transporter 1 (SLC7A1)	OTR2ZVA8	CTR1_HUMAN	Regulation of Drug Effects	[3]
High affinity copper uptake protein 1 (SLC31A1)	OTXLRTUB	COPT1_HUMAN	Regulation of Drug Effects	[3]
Inactive sodium-dependent neutral amino acid transporter B(0)AT3 (SLC6A18)	OTRKJWAS	S6A18_HUMAN	Regulation of Drug Effects	[3]
Long-chain fatty acid transport protein 1 (SLC27A1)	OTK03OZN	S27A1_HUMAN	Regulation of Drug Effects	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2145).
• [2] Exploring the structure-activity relationship of the ethylamine portion of 3-iodothyronamine for rat and mouse trace amine-associated receptor 1. J Med Chem. 2007 Jun 14;50(12):2787-98.
• [3] Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.
• [4] Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
• [5] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [6] Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Roche.
• [9] Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073.
• [10] The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6.
• [11] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [12] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [13] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [14] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [15] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [16] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [17] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [18] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [19] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [20] Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits -glycinamide ribonucleotide formyltransferase. J Med Chem. 2011 Oct 27;54(20):7150-64.
• [21] The effect of folate status on the uptake of physiologically relevant compounds by Caco-2 cells. Eur J Pharmacol. 2010 Aug 25;640(1-3):29-37. doi: 10.1016/j.ejphar.2010.04.056. Epub 2010 May 11.
• [22] SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
• [23] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [24] The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G248-54. doi: 10.1152/ajpgi.00224.2009. Epub 2009 Sep 17.
• [25] Effect of cannabinoids upon the uptake of folic acid by BeWo cells. Pharmacology. 2009;83(3):170-6. doi: 10.1159/000192587. Epub 2009 Jan 15.
• [26] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [27] The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol Pharmacol. 2012 Jul;82(1):37-46. doi: 10.1124/mol.112.077909. Epub 2012 Apr 3.
• [28] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [29] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [30] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [31] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [32] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [33] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [34] Expression of the ammonia transporter, rh C glycoprotein, in normal and neoplastic human kidney. J Am Soc Nephrol. 2006 Oct;17(10):2670-9. doi: 10.1681/ASN.2006020160. Epub 2006 Aug 23.
• [35] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [36] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [37] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [38] Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Chem Biol Interact. 2009 Feb 12;177(3):173-80. doi: 10.1016/j.cbi.2008.10.051. Epub 2008 Nov 6.
• [39] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [40] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [41] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [42] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [43] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [44] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [45] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [46] Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells. Toxins (Basel). 2023 Feb 9;15(2):140. doi: 10.3390/toxins15020140.
• [47] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [48] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [49] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [50] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [51] Ketamine promotes the amyloidogenic pathway by regulating endosomal pH. Toxicology. 2022 Apr 15;471:153163. doi: 10.1016/j.tox.2022.153163. Epub 2022 Apr 1.
• [52] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [53] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [54] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [55] Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
• [56] Human Mincle Binds to Cholesterol Crystals and Triggers Innate Immune Responses. J Biol Chem. 2015 Oct 16;290(42):25322-32. doi: 10.1074/jbc.M115.645234. Epub 2015 Aug 20.
• [57] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [58] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [59] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [60] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [61] Identification of potential biomarkers of hepatitis B-induced acute liver failure using hepatic cells derived from human skin precursors. Toxicol In Vitro. 2015 Sep;29(6):1231-9. doi: 10.1016/j.tiv.2014.10.012. Epub 2014 Oct 24.
• [62] Gene expression profiling of A549 cells exposed to Milan PM2.5. Toxicol Lett. 2012 Mar 7;209(2):136-45.
• [63] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [64] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [65] A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nat Chem Biol. 2017 Dec;13(12):1274-1279. doi: 10.1038/nchembio.2499. Epub 2017 Oct 23.
• [66] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [67] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [68] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [69] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [70] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [71] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [72] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [73] Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC Genomics. 2006 Sep 29;7:246. doi: 10.1186/1471-2164-7-246.
• [74] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [75] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [76] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [77] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [78] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [79] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [80] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [81] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [82] The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005 Jan;48(1):83-95. doi: 10.1007/s00125-004-1619-9. Epub 2004 Dec 24.
• [83] Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target. J Biol Chem. 2000 Apr 28;275(17):12612-8. doi: 10.1074/jbc.275.17.12612.
• [84] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [85] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [86] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [87] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [88] Characterization of simvastatin acid uptake by organic anion transporting polypeptide 3A1 (OATP3A1) and influence of drug-drug interaction. Toxicol In Vitro. 2017 Dec;45(Pt 1):158-165. doi: 10.1016/j.tiv.2017.09.002. Epub 2017 Sep 6.
• [89] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [90] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [91] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [92] Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin. Naunyn Schmiedebergs Arch Pharmacol. 2014 Sep;387(9):883-91. doi: 10.1007/s00210-014-1000-6. Epub 2014 Jun 20.
• [93] Post-transcriptional regulation of melanin biosynthetic enzymes by cAMP and resveratrol in human melanocytes. J Invest Dermatol. 2007 Sep;127(9):2216-27. doi: 10.1038/sj.jid.5700840. Epub 2007 Apr 26.
• [94] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [95] Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
• [96] Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
• [97] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [98] Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
• [99] UDCA and CDCA alleviate 17-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats. Toxicol Appl Pharmacol. 2016 Nov 15;311:12-25. doi: 10.1016/j.taap.2016.10.011. Epub 2016 Oct 12.
• [100] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [101] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [102] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [103] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [104] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [105] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [106] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [107] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [108] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [109] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [110] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [111] 3-Nitrobenzanthrone promotes malignant transformation in human lung epithelial cells through the epiregulin-signaling pathway. Cell Biol Toxicol. 2022 Oct;38(5):865-887. doi: 10.1007/s10565-021-09612-1. Epub 2021 May 25.
• [112] Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J. 1997 Dec 15;328 ( Pt 3)(Pt 3):739-43. doi: 10.1042/bj3280739.
• [113] Nucleoside transport in human colonic epithelial cell lines: evidence for two Na+-independent transport systems in T84 and Caco-2 cells. Biochim Biophys Acta. 1999 Jun 9;1419(1):15-22. doi: 10.1016/s0005-2736(99)00045-0.
• [114] Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network. J Biol Chem. 2001 May 18;276(20):17387-94. doi: 10.1074/jbc.M101319200. Epub 2001 Feb 26.
• [115] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [116] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [117] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [118] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [119] Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
• [120] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [121] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [122] Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther. 2012 Nov;11(11):2483-94. doi: 10.1158/1535-7163.MCT-12-0580. Epub 2012 Aug 21.
• [123] Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. J Biol Inorg Chem. 2014 Jan;19(1):17-27. doi: 10.1007/s00775-013-1051-z. Epub 2013 Oct 17.
• [124] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [125] Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.